The Use of New Technologies in the Study of Pregnancy Disorders: The OMICS Approach

Main Article Content

Silvia Visentin*
Maria Caterina Bongiorno
Maria Calanducci
Loris Marin
Erich Cosmi

Abstract

The “omics” technologies represent a new model of approach in the study of human disease. Metabolomics is defined as the quantitative measurement of the dynamic metabolic response of living systems to genetic, physical, pathological or developmental factors. Proteomics analysis of biological samples has the potential to identify novel protein expression patterns and/or changes in protein expression patterns in different developmental or disease states. In this manuscript we present the omics technologies applicated in obstetrics. The management of different pregnancy diseases could be improved by knowing their metabolic background. In this review we focused our attention on omics application for intrauterine growth restriction (IUGR), preterm birth and preeclampsia. Omics in IUGR field could help to discover novel biomarkers for early diagnosis, the molecular link between nutrient deprivation in utero and the increase in risk of developing cardiovascular illness and metabolic syndrome in adults. It could identify one or more therapeutic targets that allow to minimize the organ damage. Recently, the use of metabolomics permitted to discover significant differences in 70 proteins within the trophoblastic cells of women with pre-eclampsia when compared with healthy control women. Recently were identified proteins in cervical–vaginal fluid that could be useful to predict preterm labor in asymptomatic women: thioredoxin and interleukin-1 receptor antagonist. In conclusion, this approach can lead to new hypothesis-based medicine and provide a ‘‘shortcut’’ to obtain new biological insight.

Downloads

Download data is not yet available.

Article Details

Visentin, S., Bongiorno, M. C., Calanducci, M., Loris Marin, L. M., & Cosmi, E. (2017). The Use of New Technologies in the Study of Pregnancy Disorders: The OMICS Approach. Journal of Cardiovascular Medicine and Cardiology, 4(1), 001–004. https://doi.org/10.17352/2455-2976.000035
Review Articles

Copyright (c) 2017 Visentin S, et al.

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Licensing and protecting the author rights is the central aim and core of the publishing business. Peertechz dedicates itself in making it easier for people to share and build upon the work of others while maintaining consistency with the rules of copyright. Peertechz licensing terms are formulated to facilitate reuse of the manuscripts published in journals to take maximum advantage of Open Access publication and for the purpose of disseminating knowledge.

We support 'libre' open access, which defines Open Access in true terms as free of charge online access along with usage rights. The usage rights are granted through the use of specific Creative Commons license.

Peertechz accomplice with- [CC BY 4.0]

Explanation

'CC' stands for Creative Commons license. 'BY' symbolizes that users have provided attribution to the creator that the published manuscripts can be used or shared. This license allows for redistribution, commercial and non-commercial, as long as it is passed along unchanged and in whole, with credit to the author.

Please take in notification that Creative Commons user licenses are non-revocable. We recommend authors to check if their funding body requires a specific license.

With this license, the authors are allowed that after publishing with Peertechz, they can share their research by posting a free draft copy of their article to any repository or website.
'CC BY' license observance:

License Name

Permission to read and download

Permission to display in a repository

Permission to translate

Commercial uses of manuscript

CC BY 4.0

Yes

Yes

Yes

Yes

The authors please note that Creative Commons license is focused on making creative works available for discovery and reuse. Creative Commons licenses provide an alternative to standard copyrights, allowing authors to specify ways that their works can be used without having to grant permission for each individual request. Others who want to reserve all of their rights under copyright law should not use CC licenses.

Banks R, Selby P (2003) Clinical proteomics--insights into pathologies and benefits for patients. Lancet 362: 415–416. Link: https://goo.gl/5kf1br

Nicholson JK, Lindon JC, Holmes E (1999) “Metabonomics”: understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data. Xenobiotica 29:1181–1189. Link: https://goo.gl/Im7R3G

Robinson JM, Vandre DD, Ackerman WE (2009) Placental Proteomics: A Shortcut to Biological Insight. Placenta 23: 83–89. Link: https://goo.gl/MahbxW

Abu-Issa R, Kirby ML (2004) Take heart in the age of “Omics”. Circ Res 95: 335-336. Link: https://goo.gl/RJD36y

Edlow AG, Slonim DK, Wick HC, Hui L, Bianchi DW (2015) The pathway not taken: understanding 'omics data in the perinatal context. Am J Obstet Gynecol 213: 59.e1-172. Link: https://goo.gl/WwhL03

Ornaghi S, Mueller M, Barnea ER, Paidas MJ (2015) Thrombosis during pregnancy: risks, prevention, and treatment for mother and fetus - harvesting the power of omic technology, biomarkers and in vitro or in vivo models to facilitate the treatment of thrombosis. Birth Defects Res C Embryo Today 105: 209-225. Link: https://goo.gl/OPUm2Y

Gongora MC, Wenger NK (2015) Cardiovascular Complications of Pregnancy. Int J Mol Sci 16: 23905-23928. Link: https://goo.gl/A5UbOi

Davis EF, Newton L, Lewandowski AJ, Lazdam M, Kelly BA, et al. (2012) Preeclampsia and offspring cardiovascular health: mechanistic insights from experimental studies. Clin Sci (Lond) 123: 53-72. Link: https://goo.gl/oietrT

Wang ML, Dorer DJ, Fleming MP, Catlin EA (2004) Clinical outcomes of near-term infants. Pediatrics 114: 372-376. Link: https://goo.gl/2eeOHg

Wallace ME, Mendola P, Kim SS, Epps N, Chen Z, et al. (2016) Racial/ethnic differences in Preterm Perinatal Outcomes. Am J Obstet Gynecol In Press, Uncorrected Proof Link: https://goo.gl/3KNuLY

DeFranco E, Teramo K, Muglia L (2007) Genetic influences on preterm birth. Semin Reprod Med 25: 40-51. Link: https://goo.gl/KGnVlu

Romero R, Espinoza J, Gotsch F, Kusanovic JP, Friel LA, et al. (2006) The use of high-dimensional biology (genomics, transcriptomics, proteomics, and metabolomics) to understand the preterm parturition syndrome. BJOG 113 Suppl 3: 118-35. Link: https://goo.gl/PNBc6c

Romero R, Grivel JC, Tarca AL, Chaemsaithong P, Xu Z, et al. (2015) Evidence of Perturbations of the Cytokine Network in Preterm Labor. American journal of obstetrics and gynecology 213: 836.e1-836.e18. Link: https://goo.gl/mfq8Yi

Joshi MS, Montgomery KA, Giannone PJ, Bauer JA, Hanna MH (2017) Renal injury in neonates: use of "omics" for developing precision medicine in neonatology. Pediatr Res. 81: 271-276. Link: https://goo.gl/xrfmJk

Liong S, Di Quinzio MK, Fleming G, Permezel M, Rice GE, et al. (2013) Prediction of spontaneous preterm labour in at-risk pregnant women. Reproduction 146: 335–345. Link: https://goo.gl/OVz62I

Nápoles MD (2013) Some proteomic markers in perinatal medicine. Rev Cubana Obstet Ginecol. 39: 209–222. Link: https://goo.gl/dsoH8d

Committee on Practice Bulletins Gynecology, American College of Obstetricians and Gynecologists (2001) Intrauterine growth restriction. Clinical management guidelines for obstetrician-gynecologists. ACOG Int J Gynaecol Obstet 72: 85-96. Link: https://goo.gl/nV217y

Mandruzzato G, Antsaklis A, Botet F, Chervenak FA, Figueras F et al. (2008) Intrauterine restriction (IUGR) J Perinat Med. 36: 277–281. Link: https://goo.gl/jByZFH

Baschat AA, Viscardi RM, Hussey-Gardner B, Hashmi N, Harman C (2009) Infant neurodevelopment following fetal growth restriction: relationship with antepartum surveillance parameters. Ultrasound Obstet Gynecol. 33: 44–50. Link: https://goo.gl/gHlgan

Cecconi D, Lonardoni F, Favretto D, Cosmi E, Tucci M et al. (2011) Changes in amniotic fluid and umbilical cord serum proteomic profiles of foetuses with intrauterine growth retardation. Electrophoresis 32: 3630–3637. Link: https://goo.gl/1JLThh

Favretto D, Cosmi E, Ragazzi E, Visentin S, Tucci M et al. (2012) Cord blood metabolomic profiling in intrauterine growth restriction. Anal Bioanal Chem 402: 1109–1121. Link: https://goo.gl/pVa5GU

Paolini CL, Marconi AM, Ronzoni S, Di Noio M, Fennessey PV et al. (2001) Placental transport of leucine, phenylalanine, glycine, and proline in intrauterine growth-restricted pregnancies. J Clin Endocrinol Metab 86: 5427–5432. Link: https://goo.gl/AngXPo

Hernandez RJ, Manjarrez GG, Chagoya G (1989) Newborn humans and rats malnourished in utero: free plasma L-tryptophan, neutral amino acid and brain serotonin synthesis. Brain Res 488:1–13. Link: https://goo.gl/wFdoP7

Muhlhusler BS, Hancock SN, Bloomflied FH, Harding R (2011) Are twins growth restricted? Pediatric Research 70: 117–122. Link: https://goo.gl/oiqGNp

Cosmi E, Visentin S, Fanelli T, Mautone AJ et al (2009) Aortic intima media thickness in intrauterine growth restricted fetuses and infants: A longitudinal prospective study. Obstetrics and Gynecology, 114: 1109– 1114.

Cosmi E, Visentin S, Favretto D, Tucci M, Ragazzi E et al. (2013) Selective intrauterine growth restriction in monochorionic twin pregnancies: markers of endothelial damage and metabolomic profile. Twin Res Hum Genet 16: 816–826. Link: https://goo.gl/ThWLpZ

Dessì A, Atzori L, Noto A, Visser GH, Gazzolo D et al. (2011) Metabolomics in newborns with intrauterine growth retardation (IUGR): urine reveals markers of metabolomic syndrome - J Matern Fetal Neonatal Med Suppl 2:35-59. Link: https://goo.gl/GL6KIC

Barberini L, Noto A, Fattuoni C, Grapov D, Casanova A et al. (2014) Urinary metabolomics (GC-MS) reveals that low and high birth weight infants share elevated inositol concentrations at birth. J Matern Fetal Neonatal Med. Suppl 2: 20-26. Link: https://goo.gl/IKD4Xt

Sawicki G, Dakour J, Morrish DW (2003) Functional proteomics of neurokinin B in the placenta indicates a novel role in regulating cytotrophoblast antioxidant defences. Proteomics 3: 2044–2051. Link: https://goo.gl/VO3Dl8

Gharesi-Fard B, Zolghadri J, Kamali-Sarvestani E (2010) Proteome differences of placenta between preeclampsia and normal pregnancy. Placenta 31:121–125. Link: https://goo.gl/UfMQgK

Ma K, Jin H, Hu R, Xiong Y, Zhou S et al. (2014) A proteomic analysis of placental trophoblastic cells in preeclampsia-eclampsia. Cell Biochem Biophys 69:247–258. Link: https://goo.gl/0u3N9b

Christensen M, Kronborg CS, Eldrup N, Rossen NB, Knudsen UB et al. (2016) Preeclampsia and cardiovascular disease risk assessment - Do arterial stiffness and atherosclerosis uncover increased risk ten years after delivery? Pregnancy Hypertens 6:110-114. Link: https://goo.gl/KqWKs8